Page last updated: 2024-11-12
6-o-desmethyl donepezil
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
6-O-desmethyl donepezil: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 14553555 |
| CHEBI ID | 185875 |
| SCHEMBL ID | 4554589 |
| MeSH ID | M0529212 |
Synonyms (22)
| Synonym |
|---|
| FT-0666155 |
| CHEBI:185875 |
| 6-o-desmethyldonepezil |
| 120013-56-1 |
| 2-[(1-benzylpiperidin-4-yl)methyl]-6-hydroxy-5-methoxy-2,3-dihydroinden-1-one |
| 6-o-desmethyl donepezil |
| SCHEMBL4554589 |
| donepezil (m1) |
| 556XXE4I5F , |
| donepezil (metabolite m1) |
| 1-benzyl-4-((6-hydroxy-5-methoxy-1-oxo-indan-2-yl)methyl)piperidine |
| 1h-inden-1-one, 2,3-dihydro-6-hydroxy-5-methoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)- |
| unii-556xxe4i5f |
| DTXSID60561627 |
| 2-[(1-benzylpiperidin-4-yl)methyl]-6-hydroxy-5-methoxy-2,3-dihydro-1h-inden-1-one |
| J-004238 |
| AKOS030255439 |
| FT-0666156 |
| 1h-inden-1-one, 2,3-dihydro-6-hydroxy-5-methoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- |
| Q27261288 |
| 2,3-dihydro-6-hydroxy-5-methoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- |
| PD099364 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The proposed method was successfully applied for the estimation of the drug in real time plasma samples for pharmacokinetic studies." | ( A rapid and sensitive LC-MS/MS method for quantification of donepezil and its active metabolite, 6-o-desmethyl donepezil in human plasma and its pharmacokinetic application. Damaramadugu, R; Inamadugu, JK; Karra, VK; Kondreddy, N; Pilli, NR; Rao, JV, 2011) | 0.59 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| piperidines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.16
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.16) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||